Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 6/2016

01-06-2016 | Letter to the Editors

A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome

Authors: Elizabeth Hansen, Deepak Sahasrabudhe, Lynn Sievert

Published in: Cancer Immunology, Immunotherapy | Issue 6/2016

Login to get access

Excerpt

Dear Editors, …
Literature
1.
2.
Mekinist (trametinib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation (2015)  
3.
Tafinlar (dabrafenib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation (2015)
4.
Pembrolizumab (keytruda) [package insert]. Whitehouse Station, NJ: Merk & Co., Inc. (2015)
5.
Keytruda (pembrolizumab) [package insert]. Merck & Co., Inc., Whitehouse Station, NJ (2014)
Metadata
Title
A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome
Authors
Elizabeth Hansen
Deepak Sahasrabudhe
Lynn Sievert
Publication date
01-06-2016
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 6/2016
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-016-1835-4

Other articles of this Issue 6/2016

Cancer Immunology, Immunotherapy 6/2016 Go to the issue

Original Article

Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma

Original Article

Differential immunomodulatory activity of tumor cell death induced by cancer therapeutic toll-like receptor ligands

Original Article

Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma

Original Article

Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells

Review

Strategies to genetically engineer T cells for cancer immunotherapy

Original Article

2′–5′ Oligoadenylate synthetase-like 1 (OASL1) deficiency in mice promotes an effective anti-tumor immune response by enhancing the production of type I interferons
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits